Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
There has recently been a resurgence of interest in psychedelics, substances that profoundly alter perception and cognition and have recently demonstrated therapeutic efficacy to treat anxiety, depression, and addiction in the clinic. The receptor mechanisms that drive their molecular and behavioral effects involve activation of cortical serotonin 5-HT 2A receptors, but the responses of specific cellular populations remain unknown. Here, we provide evidence that a small subset of 5-HT 2A -expressing excitatory neurons is directly activated by psychedelics and subsequently recruits other select cell types including subpopulations of inhibitory somatostatin and parvalbumin GABAergic interneurons, as well as astrocytes, to produce distinct and regional responses. To gather data regarding the response of specific neuronal populations, we developed methodology for fluorescence-activated cell sorting (FACS) to segregate and enrich specific cellular subtypes in the brain. These methods allow for robust neuronal sorting based on cytoplasmic epitopes followed by downstream nucleic acid analysis, expanding the utility of FACS in neuroscience research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons
Rudy, B., Fishell, G., Lee, S., & Hjerling‐Leffler, J. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20853 · Cited by 1,420
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 2×
“Recently, there has been a resurgence of interest in the clinical study of psychedelics, and remarkable efficacy has been demonstrated in clinical trials for various psychiatric conditions such as anxiety (Gasser et al., 2014; Grob et al., 2011) and addiction (Bogenschutz et al.”
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 4×
“Interestingly, blood flow and BOLD responses in the cortex are decreased following psilocybin (Carhart-Harris et al., 2012), leaving open questions surrounding neurovascular coupling during the psychedelic state (Spain et al., 2015).”
InfluentialPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“…there has been a resurgence of interest in the clinical study of psychedelics, and remarkable efficacy has been demonstrated in clinical trials for various psychiatric conditions such as anxiety (Gasser et al., 2014; Grob et al., 2011) and addiction (Bogenschutz et al., 2015; Johnson et al., 2014).”
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“, 1984; Halberstadt, 2015) in both humans (Vollenweider et al., 1998) and rodents (Gresch et al.”
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“Extensive work in rodents indicates that the cortex is a critical locus for their behavioral effects (Gonzalez-Maeso et al., 2007; Gresch et al., 2007).”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2×
“…there has been a resurgence of interest in the clinical study of psychedelics, and remarkable efficacy has been demonstrated in clinical trials for various psychiatric conditions such as anxiety (Gasser et al., 2014; Grob et al., 2011) and addiction (Bogenschutz et al., 2015; Johnson et al., 2014).”
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 3×
“In humans, psychedelics can lead to increased [(18)F]-fluorodeoxyglucose uptake (Vollenweider et al., 1997), decreased blood flow and blood oxygen level dependent (BOLD) signal (Carhart-Harris et al.”
InfluentialRecent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 2×
“Although many psychedelics exhibit complex receptor pharmacology (Halberstadt and Geyer, 2011; Nichols, 2016), all are believed to exhibit their primary effects through activation of the brain serotonin 5-HT2A receptor (Glennon et al., 1984; Halberstadt, 2015) in both humans (Vollenweider et al.”
González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297
Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229 · cited 2×
“Interestingly, a subset of deep pyramidal cells in layer V of the prefrontal cortex is directly depolarized by 5-HT2A receptor activation in brain slices, implicating an intracortical mechanism in the action of psychedelics (Beique et al., 2007).”
Weber (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00036 · Cited by 205
Nichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · cited 1×
“…example, systemic administration of psychedelics produces widespread gene expression changes in the prefrontal cortex (PFC) (Nichols et al., 2003; Nichols and Sanders-Bush, 2002) and somatosensory cortex (SSC) (Gonzalez-Maeso et al., 2003), but these data refer only to entire structures and not…”
BackgroundSelf-citationGandhi, G. K., Cruz, N. F., Ball, K. K., & Dienel, G. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06333.x · Cited by 162
Rossier, J., Bernard, A., Cabungcal, J.-H., Perrenoud, Q., Savoye, A., Gallopin, T., Hawrylycz, M., Cuénod, M., Do, K., Urban, A., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.162 · Cited by 101 · cited 8×
“A clear segregation between neuronal and nonneuronal populationswas apparent based on NeuN-PE immunoreactivity (IR) and these populationswere verified by downstreamQPCR analysis (Fig.”
MethodInfluential
Cited by
Psychedelics as Medicines: An Emerging New Paradigm
Nichols, D., Johnson, M., & Nichols, C. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 370
Self-citationThe neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Psychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155
Self-citationJefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
Metadata
- Authors
- Martin, D. A., & Nichols, C. D.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 11
- Pages
- 262-277
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2515280853
- Cited by
- 86
- References
- 16
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.